Why Use Flow Cytometry in Cancer Research?
- It Analyzes Individual Cells
Many laboratory methods measure the average signal produced by all cells in a sample.
An average measurement may hide important differences between smaller populations.
For example, a tumor sample may show moderate expression of a therapeutic target when measured in bulk. Flow cytometry may reveal that one population expresses the target strongly, another expresses it weakly, and a third population does not express it at all.
This single-cell information helps researchers determine:
• What percentage of cells express a marker
• How strongly each cell expresses the marker
• Whether separate positive and negative populations are present
• Which other markers are expressed by the same cells
• Whether a treatment affects all cells or only a subset
- It Can Measure Multiple Markers Simultaneously
Cancer cells and immune cells are rarely identified using one marker alone.
A flow cytometry panel can combine lineage, viability, activation, differentiation, signaling, and functional markers.
For example, researchers may first identify live immune cells and then divide them into:
• T cells
• B cells
• NK cells
• Monocytes
• Macrophages
• Dendritic cells
• Granulocytes
• Myeloid-derived suppressor cell populations
Each population can then be examined for additional markers associated with activation, exhaustion, proliferation, cytokine production, or immune suppression.
- It Can Detect Heterogeneous Populations
Cancer is biologically heterogeneous.
Differences may exist:
• Between patients
• Between primary and metastatic tumors
• Between separate regions of the same tumor
• Between treatment-responsive and resistant cells
• Between cells collected before and after therapy
• Between cancer cells and cells in the surrounding microenvironment
Flow cytometry helps identify these differences by separating the sample into measurable cellular populations.
- It Can Analyze Large Numbers of Cells
Flow cytometers can evaluate many individual events during one acquisition.
This allows researchers to examine population frequencies and identify smaller subsets that may not be obvious through methods that inspect fewer cells.
The number of events required depends on the frequency of the target population, the complexity of the sample, and the precision required by the experiment.
- It Can Physically Isolate Selected Cells
Fluorescence-activated cell sorting can separate selected cancer or immune-cell populations from a mixed sample.
The isolated cells can then be used for:
• Cell culture
• DNA analysis
• RNA analysis
• Protein analysis
• Functional assays
• Drug testing
• Microscopy
• Clonal expansion
• Single-cell sequencing
Studying Blood Cancers with Flow Cytometry
Flow cytometry is especially important in research involving leukemia, lymphoma, myeloma, and other hematologic cancers.
Blood, bone marrow, lymph-node, and related samples can often be converted into single-cell suspensions more easily than solid tumors.
Researchers can use combinations of markers to distinguish abnormal populations from normal blood-cell development.
The National Cancer Institute’s clinical flow cytometry programs use immunophenotyping to study hematologic cancers, detect abnormal B- and T-cell populations, evaluate therapeutic targets, and monitor responses under research protocols.
Immunophenotyping Cancer Cells
Immunophenotyping is the process of identifying cells based on the proteins they express.
Flow cytometry immunophenotyping can evaluate proteins on the cell surface or inside the cell.
In blood-cancer research, immunophenotyping may be used to examine:
• Cell lineage
• Maturation stage
• Abnormal marker combinations
• Loss of expected markers
• Unusually strong or weak marker expression
• Expression of therapeutic targets
• Changes following treatment
A researcher studying an abnormal blood population may begin with broad lineage markers and then add markers associated with a specific leukemia or lymphoma subtype.
No cancer population should be identified using one marker alone when that marker may also be expressed by normal cells.
The complete marker pattern, sample type, controls, morphology, molecular findings, and research purpose should all be considered.
Studying Solid Tumors with Flow Cytometry
Solid tumors are more difficult to analyze because the tissue must first be dissociated into a single-cell suspension.
A solid-tumor sample may contain:
• Cancer cells
• T cells
• B cells
• NK cells
• Macrophages
• Monocytes
• Dendritic cells
• Granulocytes
• Fibroblasts
• Endothelial cells
• Dead cells
• Tissue debris
The dissociation method must release enough cells while preserving viability and the markers required by the study.
Mechanical or enzymatic dissociation may affect:
• Cell recovery
• Surface-marker expression
• Cell viability
• Population frequency
• Cell activation
• Fluorescence background
Researchers should validate the tissue-processing method before using it throughout a large study.
Studying the Tumor Immune Microenvironment
The tumor microenvironment includes the cancer cells and the noncancerous cells, signals, and structures surrounding them.
Immune cells are an important part of this environment and may either attack the tumor or contribute to immune suppression and cancer progression.
Multiparameter flow cytometry can characterize the immune landscape of the tumor microenvironment at the single-cell level.
Researchers may use flow cytometry to measure:
• The percentage of immune cells in the sample
• The types of immune cells present
• Activation-marker expression
• Immune-checkpoint expression
• Cytokine production
• Proliferation
• Cytotoxic proteins
• Memory and differentiation states
• Myeloid-cell phenotypes
• Regulatory or suppressive populations
T-Cell Profiling in Cancer Research
T cells are frequently studied because of their role in antitumor immunity and cancer immunotherapy.
A cancer-research flow panel may examine:
• CD4 and CD8 T-cell populations
• Naive T cells
• Central-memory T cells
• Effector-memory T cells
• Terminally differentiated T cells
• Regulatory T-cell-enriched populations
• Activated T cells
• Proliferating T cells
• Cytokine-producing T cells
• Exhaustion-associated phenotypes
• Tumor-infiltrating lymphocytes
Markers should be selected according to the specific biological question.
For example, identifying the broad CD8 T-cell population requires fewer markers than determining its activation, memory, proliferation, checkpoint, and functional states.
Regulatory T-Cell Research
Regulatory T cells are commonly investigated because they can limit immune activation.
A flow cytometry strategy may begin with live CD3-positive CD4-positive cells and then examine markers associated with a regulatory T-cell-enriched phenotype.
CD25-high and CD127-low expression may help identify a regulatory T-cell-enriched population. FOXP3 can provide additional information but requires intracellular or intranuclear staining and should only be interpreted when the fixation and permeabilization workflow is appropriate.
No single marker should be treated as definitive in every tissue or disease setting.
NK-Cell Profiling
Natural killer cells contribute to the recognition and destruction of abnormal cells.
Cancer-research panels may measure:
• NK-cell frequency
• Activation receptors
• Inhibitory receptors
• Cytotoxic proteins
• Cytokine production
• Proliferation
• Degranulation
• Immune-checkpoint expression
• Changes following therapy
The panel should distinguish NK cells from T cells and other lymphocyte populations using an appropriate combination of lineage markers.
Myeloid-Cell Profiling
Tumors can contain multiple myeloid populations, including:
• Monocytes
• Macrophages
• Dendritic cells
• Granulocytes
• Immature myeloid populations
• Myeloid-derived suppressor cell populations
These cells may participate in inflammation, antigen presentation, tissue remodeling, angiogenesis, phagocytosis, or immune suppression.
Myeloid populations can be challenging to analyze because:
• Several populations share markers
• Marker expression may be continuous
• Tissue processing can alter the phenotype
• Autofluorescence may be high
• Dead cells and debris can interfere with gating
• Definitions may vary between studies
The National Cancer Institute uses flow cytometry in projects involving immunosuppressive myeloid populations and other cancer-associated immune cells.
Measuring Immune-Checkpoint Markers
Immune-checkpoint pathways help regulate immune responses.
Cancer cells and immune cells may express checkpoint or checkpoint-related proteins that influence antitumor activity.
Flow cytometry can determine:
• Which cell population expresses the marker
• What percentage of the population is positive
• The relative level of expression
• Whether multiple checkpoint markers are co-expressed
• Whether expression changes after stimulation or treatment
Checkpoint expression should be interpreted carefully.
Expression of one marker does not automatically prove that a cell is functionally exhausted, suppressed, or unable to respond.
Researchers may need to combine surface markers with:
• Cytokine production
• Proliferation
• Degranulation
• Cytotoxicity
• Signaling measurements
• Additional differentiation markers
Measuring Therapeutic Targets
Flow cytometry can measure whether cancer or immune cells express a potential therapeutic target.
This is useful during research involving:
• Monoclonal antibodies
• Antibody-drug conjugates
• Bispecific antibodies
• CAR T-cell therapies
• CAR NK-cell therapies
• Targeted immune therapies
• Receptor-blocking drugs
Researchers can evaluate:
• The percentage of target-positive cells
• The intensity of target expression
• Differences between cancer-cell populations
• Changes following treatment
• Loss of the target in resistant cells
• Target expression on healthy cells
The National Cancer Institute uses flow cytometry to assess therapeutic targets and support studies involving cell therapies such as CAR T cells.
Receptor-Occupancy Studies
Receptor occupancy describes how much of a cellular receptor is bound by a therapeutic molecule.
Flow cytometry may be used to compare:
• Total receptor expression
• Unoccupied receptor
• Drug-bound receptor
• Receptor expression before and after treatment
Receptor-occupancy assays require carefully selected antibody clones.
An antibody used to detect the receptor may compete with the therapeutic molecule for the same binding site. If this occurs, the assay may underestimate total receptor expression or produce a misleading result.
Controls and assay-specific validation are necessary.
Measuring Cancer-Cell Viability
Viability measurements help determine whether cancer cells remain alive after treatment.
A viability dye can distinguish cells with damaged membranes from cells that exclude the dye.
Flow cytometry viability analysis may be used to compare:
• Untreated cells
• Vehicle-treated cells
• Drug-treated cells
• Different drug concentrations
• Different treatment times
• Combination therapies
• Cancer cells and noncancerous control cells
Viability should be measured within the identified cancer-cell population rather than only across the entire sample when several cell types are present.
Measuring Apoptosis
Apoptosis is a regulated form of cell death and an important endpoint in cancer drug research.
Common flow cytometry approaches include:
• Annexin V binding
• Membrane-integrity dyes
• Caspase-activity probes
• Mitochondrial membrane-potential dyes
• TUNEL-based measurements
• Intracellular apoptosis-related proteins
The National Cancer Institute lists Annexin V, TUNEL, caspase, mitochondrial, and related apoptosis assays among the flow cytometry applications used by its research facilities.
Annexin V and a membrane-integrity dye are often used together to distinguish populations consistent with:
• Viable cells
• Early apoptotic cells
• Late apoptotic or membrane-damaged cells
These classifications should be interpreted within the context of the treatment, timing, cell type, and controls.
Measuring Cell-Cycle Distribution
Cancer cells often have altered control of cell division.
DNA-binding dyes can be used to estimate the amount of DNA in each cell and determine the proportion of cells in different cell-cycle regions.
A typical DNA-content analysis may identify populations corresponding to:
• G0/G1
• S phase
• G2/M
Flow cytometry can also measure:
• DNA synthesis
• Mitotic markers
• Proliferation-associated proteins
• Cell-cycle arrest
• Sub-G1 DNA content
Cell-cycle and DNA-synthesis assays are established applications of flow cytometry in cancer-research facilities.
Cell aggregates must be excluded carefully because two cells passing together can appear to have increased DNA content.
Measuring Cell Proliferation
Flow cytometry can measure cell proliferation using:
• Dye-dilution methods
• DNA-synthesis measurements
• Intracellular proliferation markers
• Cell counts over time
• Cell-cycle analysis
Dye-dilution methods label cells with a fluorescent dye. The fluorescence becomes lower as the dye is divided between daughter cells during cell division.
Researchers can compare proliferation between:
• Treatment conditions
• Cancer-cell lines
• Immune-cell populations
• Responders and nonresponders
• Coculture conditions
• Drug-sensitive and resistant cells
Measuring Intracellular Signaling
Cancer cells may have abnormal signaling pathways that support survival, proliferation, migration, or treatment resistance.
Phospho-flow cytometry uses antibodies that recognize phosphorylated signaling proteins.
Researchers may use phospho-flow to measure:
• Baseline signaling activity
• Responses to growth factors
• Responses to cytokines
• Pathway inhibition by a drug
• Differences between cancer-cell subsets
• Signaling within immune populations
• Resistance-associated signaling
Intracellular phosphoprotein analysis is an established flow cytometry application used by NCI research facilities.
Phosphorylation can change rapidly, so sample timing, fixation, temperature, and handling must be tightly controlled.
Measuring Cytokine Production
Intracellular cytokine staining can identify which cells produce selected cytokines following stimulation.
A typical workflow may include:
- Stimulating the cells.
- Adding a secretion-blocking reagent when appropriate.
- Staining surface markers.
- Fixing the cells.
- Permeabilizing the cells.
- Staining intracellular cytokines.
- Identifying cytokine-producing populations by flow cytometry.
This approach can determine whether cytokine production comes from:
• CD4 T cells
• CD8 T cells
• NK cells
• Monocytes
• Macrophages
• Other selected populations
Intracellular cytokine detection is among the applications supported by NCI flow cytometry facilities.
Evaluating Cancer Drug Responses
Flow cytometry can evaluate how cancer and immune cells respond to an experimental treatment.
Possible endpoints include:
• Viability
• Apoptosis
• Necrosis
• Proliferation
• Cell-cycle arrest
• Target expression
• Receptor occupancy
• Signaling inhibition
• DNA damage
• Oxidative stress
• Mitochondrial changes
• Immune activation
• Cytokine production
• Cancer-cell killing
Measuring several endpoints can provide more information than measuring cell viability alone.
For example, a treatment may not immediately kill a cancer cell but may stop proliferation, alter signaling, or make the cell more sensitive to an immune response.
Comparing Cancer Cells with Healthy Cells
A treatment that affects cancer cells may also affect healthy cells.
Researchers may compare:
• Cancer cells and normal tissue cells
• Malignant and nonmalignant blood populations
• Tumor cells and immune cells
• Drug-sensitive and drug-resistant cancer cells
• Target-positive and target-negative cells
Flow cytometry can help determine whether an effect is selective for the cancer population or broadly toxic across the sample.
Measuring Immune-Mediated Cancer-Cell Killing
Flow cytometry can be used in coculture assays containing cancer cells and immune effector cells.
Possible effector populations include:
• T cells
• CAR T cells
• NK cells
• CAR NK cells
• Macrophages
• Engineered immune cells
The cancer cells and immune cells must be distinguishable using:
• Lineage markers
• Cell-tracking dyes
• Fluorescent proteins
• Tumor-associated markers
Researchers can then measure:
• Cancer-cell death
• Effector-cell activation
• Degranulation
• Cytokine production
• Effector-cell proliferation
• Target-cell loss
• Changes in checkpoint expression
A proper analysis should identify viability separately within the cancer-cell and immune-cell gates.
Supporting Cell-Therapy Research
Flow cytometry can support several stages of cell-therapy development.
Researchers may measure:
• Cell identity
• Cell purity
• Transduction or engineering efficiency
• CAR expression
• Viability
• Memory phenotype
• Activation state
• Exhaustion-associated markers
• Proliferation
• Cytokine production
• Degranulation
• Target-cell killing
• Persistence-related phenotypes
NCI-supported flow cytometry programs use the technology in research involving CAR T-cell therapy and other cancer clinical protocols.
Detecting Measurable Residual Disease
Measurable residual disease, or MRD, refers to a small number of cancer cells that remain after treatment and cannot necessarily be identified through routine morphological examination.
Multiparameter flow cytometry can identify residual leukemia cells by detecting leukemia-associated immunophenotypes or cell patterns that differ from normal development.
MRD status can provide important information about treatment response and risk in acute leukemia, although assay design, timing, standardization, and interpretation remain important challenges.
An MRD flow cytometry assay requires:
• A high-quality sample
• Enough acquired cells
• A validated antibody panel
• Knowledge of normal cell development
• Careful exclusion of artifacts
• Standardized instrument performance
• Trained data interpretation
• Clearly defined reporting criteria
MRD testing used for patient care must be conducted in an appropriately validated clinical laboratory. A general research flow cytometry assay should not be treated as a clinical MRD test.
Approaches to Flow Cytometry MRD Analysis
Leukemia-Associated Immunophenotype Approach
A leukemia-associated immunophenotype is identified at diagnosis.
The researcher then looks for cells with the same or a related marker pattern after treatment.
One challenge is that the cancer phenotype may change during treatment or relapse.
Different-from-Normal Approach
The post-treatment sample is compared with expected patterns of normal cell maturation.
Cells with abnormal combinations, intensities, or developmental patterns may be investigated as possible residual disease.
This approach requires strong knowledge of normal and regenerating bone-marrow populations.
Detecting Rare Cancer-Associated Cells
Flow cytometry may be used to study rare cancer-associated populations, including:
• Residual leukemia cells
• Cancer stem-like populations
• Rare treatment-resistant cells
• Circulating tumor cells
• Small metastatic populations
• Rare immune subsets
Rare-event analysis is vulnerable to false-positive events caused by:
• Debris
• Dead cells
• Doublets
• Cell aggregates
• Nonspecific staining
• Autofluorescence
• Compensation or unmixing errors
• Sample contamination
• Acquisition instability
Enough total events must be acquired to support the intended analysis.
Studying Circulating Tumor Cells
Circulating tumor cells are cancer-associated cells found in the bloodstream.
They may be greatly outnumbered by normal blood cells, which makes their detection and purification challenging. Cytometric strategies often combine positive markers associated with the tumor with exclusion markers for unwanted blood populations.
A circulating-tumor-cell research strategy may include:
• Enrichment before flow cytometry
• Exclusion of dead cells
• Exclusion of leukocytes
• Positive tumor-associated markers
• Multiple confirmation markers
• Careful rare-event controls
• Sorting for downstream characterization
Marker-based detection can miss tumor cells that do not express the selected markers. Researchers should avoid assuming that every circulating tumor cell will have one uniform phenotype.
Cancer Stem-Like Cell Research
Some cancer studies investigate smaller populations with characteristics associated with self-renewal, treatment resistance, tumor initiation, or recurrence.
Flow cytometry may be used to identify and sort populations based on:
• Surface-marker combinations
• Enzyme activity
• Dye-efflux properties
• Metabolic probes
• Reporter expression
• Functional characteristics
A marker-defined population should not automatically be described as a functional cancer stem-cell population.
Functional assays are usually needed to determine whether the cells actually demonstrate the proposed biological behavior.
Cell Sorting in Cancer Research
Fluorescence-activated cell sorting can isolate selected cancer or immune-cell populations.
Researchers may sort:
• Tumor cells from immune cells
• Target-positive and target-negative cancer cells
• Drug-resistant populations
• Immune-cell subsets
• Reporter-positive engineered cells
• Live cancer stem-like populations
• Single cancer cells
• Rare residual populations
Sorted cells may then be used for:
• Sequencing
• Cell culture
• Drug-response assays
• Protein analysis
• Functional testing
• Imaging
• Clonal expansion
The panel should be designed using live-cell-compatible markers when the sorted cells need to remain alive.
Sample Types Used in Cancer Flow Cytometry
Cancer research may involve:
• Peripheral blood
• Bone marrow
• Lymph-node samples
• Tumor biopsies
• Surgically removed tumors
• Fine-needle aspirates
• Pleural or abdominal fluids
• Cell lines
• Patient-derived cells
• Organoids
• Spheroids
• Xenograft-derived tissues
• Coculture systems
Each sample type presents different challenges.
Blood and bone marrow may contain large numbers of red blood cells.
Solid tumors require dissociation.
Fluids may contain low cell numbers.
Organoids and spheroids require disruption into a single-cell suspension.
Cell lines may not represent the heterogeneity of a patient tumor.
Cancer Cell Lines
Cancer cell lines are commonly used during early assay development because they are easier to grow and standardize than many primary tumor samples.
They may be useful for:
• Antibody testing
• Drug screening
• Apoptosis assays
• Cell-cycle studies
• Signaling experiments
• Target-expression analysis
• Coculture development
• Sorting optimization
However, long-established cell lines may differ from primary tumors in genetics, growth, metabolism, receptor expression, and treatment response.
Important findings should be evaluated in more biologically relevant models when possible.
Patient-Derived Tumor Samples
Patient-derived samples may better represent actual tumor heterogeneity but can be more difficult to process.
Challenges may include:
• Limited sample size
• Low viability
• Variable tissue composition
• Prior treatment effects
• High autofluorescence
• Large amounts of debris
• Donor-to-donor variability
• Unpredictable marker expression
• Delays between collection and processing
The workflow should be designed to preserve as much usable material as possible.
Organoids and Three-Dimensional Tumor Models
Organoids and spheroids may provide more complex models than standard two-dimensional cell cultures.
Flow cytometry can be used after the model is dissociated into individual cells.
Researchers may examine:
• Cancer-cell viability
• Drug penetration effects
• Treatment-resistant populations
• Immune-cell infiltration
• Cancer and stromal-cell interactions
• Target expression
• Cellular composition
The dissociation method must be validated because it may cause cell loss or alter the markers being measured.
A Basic Cancer Flow Cytometry Workflow
A cancer flow cytometry experiment may include the following steps:
- Define the biological question.
- Select the sample type.
- Identify the cell populations that must be measured.
- Select the required markers.
- Design the fluorophore panel.
- Prepare the necessary controls.
- Convert the sample into a single-cell suspension.
- Count the cells and measure viability.
- Stain the cells.
- Wash and resuspend the sample.
- Configure and quality-check the instrument.
- Acquire enough events.
- Apply the gating strategy.
- Review compensation or spectral unmixing.
- Compare the experimental groups.
- Confirm important findings using appropriate controls or additional methods.
Step 1: Define the Biological Question
The flow cytometry panel should be built around a specific question.
Examples include:
• Does a drug cause apoptosis in the cancer cells?
• Does treatment reduce receptor expression?
• Which immune cells are present in the tumor?
• Are CD8 T cells activated after therapy?
• Does a resistant cancer population remain after treatment?
• Do cancer cells express the intended therapeutic target?
• Which cells produce a selected cytokine?
• Can a rare cancer-cell population be isolated?
A panel should not begin with the question, “How many markers can be added?”
It should begin with the minimum markers needed to answer the biological question accurately.
Step 2: Select the Population-Identification Markers
The panel must distinguish the population of interest from other cells in the sample.
A solid-tumor immune-profiling panel may require markers to separate:
• Immune and nonimmune cells
• T cells and other lymphocytes
• Myeloid and lymphoid populations
• Cancer cells and stromal cells
• Live and dead cells
A blood-cancer panel may require markers that identify:
• Lineage
• Maturation
• Abnormal antigen combinations
• Therapeutic targets
• Residual abnormal populations
Step 3: Add Functional Markers
After the cell populations can be identified, functional markers may be added.
These may measure:
• Activation
• Exhaustion-associated phenotypes
• Proliferation
• Cytotoxicity
• Cytokine production
• Signaling
• Apoptosis
• Cell cycle
• Receptor occupancy
• Drug response
Adding functional markers before the populations can be identified may produce data that are difficult to interpret.
Step 4: Select the Fluorophores
Fluorophore selection should consider:
• Marker-expression level
• Fluorophore brightness
• Co-expression patterns
• Spillover or spectral similarity
• Instrument configuration
• Sample autofluorescence
• Fixation compatibility
• Tandem-dye stability
• Importance of the marker
Dim or critical markers generally require fluorophores that provide strong separation.
Highly expressed markers may be assigned to more moderate fluorophores.
Markers expressed on the same cells should not automatically be paired with fluorophores that create severe spread into one another.
Conventional and Spectral Flow Cytometry in Cancer Research
Conventional and spectral cytometers can both support cancer research.
Conventional flow cytometry may be suitable for:
• Established panels
• Smaller experiments
• Routine cell-line assays
• Basic immune profiling
• Apoptosis and cell-cycle studies
• Validated blood-cancer panels
Spectral flow cytometry may be particularly useful for:
• High-parameter immune profiling
• Complex tumor samples
• Highly autofluorescent cells
• Limited samples that cannot be divided across several tubes
• Measuring many markers on the same cells
Spectral flow does not remove the need for thoughtful panel design, antibody titration, controls, and data review.
High-Parameter Flow Cytometry in Cancer Research
High-parameter flow cytometry allows researchers to evaluate many markers on the same cells.
It may be useful for studying:
• Tumor immune heterogeneity
• Detailed T-cell states
• Myeloid diversity
• Immune-checkpoint combinations
• Treatment-response signatures
• Rare populations
• Cell-therapy products
• Multiple cancer and immune populations in one sample
More parameters do not automatically create a better experiment.
Every marker should have a clear role in identifying a population, answering the biological question, or supporting data interpretation.
Important Controls for Cancer Flow Cytometry
- Unstained Control
The unstained control shows the natural autofluorescence of the sample.
This is particularly important for tumor cells, macrophages, granulocytes, fixed samples, and dissociated tissues.
- Single-Stained Controls
Single-stained controls are used for conventional compensation or spectral-reference controls.
A suitable control is generally needed for each fluorophore.
- Fluorescence-Minus-One Controls
An FMO control contains every fluorophore except the marker being evaluated.
FMOs may be useful for:
• Dim markers
• Continuous expression patterns
• Rare populations
• Checkpoint markers
• Activation markers
• Gates affected by fluorescence spread
- Viability Controls
A dead-cell control can help establish the viability-dye-positive population.
- Biological Positive and Negative Controls
These may include:
• Untreated cells
• Vehicle controls
• Known target-negative cells
• Known target-positive cells
• Stimulated immune cells
• Drug-sensitive cells
• Drug-resistant cells
• Untransfected cells
• Reporter-negative cells
- Isotype Controls
Isotype controls may help investigate certain nonspecific-binding problems, but they do not replace FMOs, biological controls, or unstained controls for routine gate placement.
A General Gating Strategy for Cancer Samples
A cancer flow cytometry gating strategy may include:
- Time Gate
A time gate can identify interruptions, clogs, pressure changes, or unstable acquisition periods.
- Cell and Debris Gate
Forward and side scatter may help separate intact cells from obvious debris.
This gate should not be so restrictive that it removes small, dying, or unusually shaped target cells that are relevant to the study.
- Singlet Gate
Doublets and aggregates should be excluded using pulse-area, height, or width measurements.
- Viability Gate
Dead cells should be removed when the analysis focuses on live-cell phenotypes.
- Broad Population Gate
Examples include:
• Immune versus nonimmune cells
• Hematopoietic versus nonhematopoietic cells
• Cancer cells versus immune cells
• Lymphoid versus myeloid cells
- Lineage and Subset Gates
The broad populations can then be divided into the required lineages and subsets.
- Functional-Marker Analysis
Activation, checkpoint, proliferation, apoptosis, cytokine, or signaling markers should be evaluated within clearly identified populations.
Autofluorescence in Cancer Samples
Autofluorescence is naturally produced by cells and tissues.
It may be particularly strong in:
• Tumor cells
• Macrophages
• Granulocytes
• Lung tissue
• Digestive tissue
• Brain tissue
• Dead or damaged cells
• Fixed samples
Autofluorescence can reduce the separation between negative cells and dim positive cells.
Researchers may address it through:
• Proper unstained controls
• Careful fluorophore selection
• Exclusion of dead cells
• Consistent sample processing
• Spectral autofluorescence extraction when appropriate
• Avoiding dim fluorophores in highly autofluorescent regions
Common Problems in Cancer Flow Cytometry
- Low Viability
Possible causes include:
• Delayed sample processing
• Harsh tissue dissociation
• Long staining procedures
• Incorrect buffers
• Excessive centrifugation
• Toxic treatments
• Poor starting-sample quality
- Excessive Debris
Possible causes include:
• Necrotic tumors
• Overly harsh dissociation
• Cell death during storage
• Incomplete washing
• Inappropriate filtering
- Cell Clumping
Possible causes include:
• Released DNA from dead cells
• Incomplete tissue dissociation
• High cell concentration
• Inadequate mixing
• Damaged cells
• Long sample-storage periods
- Weak Marker Expression
Possible causes include:
• Low antigen density
• Enzymatic removal of the marker
• Incorrect antibody clone
• Poor fluorophore assignment
• Under-titrated antibody
• Treatment-related target loss
- High Background
Possible causes include:
• Dead cells
• Fc-receptor binding
• Excess antibody
• Inadequate washing
• Autofluorescence
• Nonspecific staining
• Poor control selection
- Unexpected Population Frequencies
Possible causes include:
• Selective cell loss
• Incomplete tissue dissociation
• Incorrect gating
• Unequal sample handling
• Low event counts
• Treatment-related cell death
• Batch effects
Limitations of Flow Cytometry in Cancer Research
- It Requires a Single-Cell Suspension
Standard flow cytometry does not preserve the original location of cells within a tissue.
Researchers may know which cell populations are present but not where they were positioned in relation to the tumor.
Imaging, histology, or spatial methods may be needed to provide tissue-location information.
- Tissue Processing Can Change the Sample
Dissociation can cause:
• Cell loss
• Cell death
• Receptor cleavage
• Cellular activation
• Changes in population frequency
- Marker Expression Does Not Always Equal Function
A cell expressing an activation or exhaustion-associated marker may not necessarily behave as expected.
Functional assays may be needed.
- Rare-Event Analysis Is Vulnerable to Artifacts
Debris, doublets, nonspecific staining, and acquisition instability can resemble rare cells.
- Panels Require Extensive Validation
An antibody that works alone may behave differently within a large panel.
- Flow Cytometry Does Not Replace Every Other Method
Cancer research may also require:
• Histology
• Imaging
• Sequencing
• Cytogenetics
• Molecular testing
• Functional assays
• Protein analysis
• Clinical evaluation
Flow cytometry is most powerful when used as part of a broader experimental strategy.
Best Practices for Cancer Research Using Flow Cytometry
To improve data quality:
- Define the biological question before designing the panel.
- Identify the minimum markers needed to answer the question.
- Validate the tissue-dissociation method.
- Process samples consistently and promptly.
- Count the cells and measure viability.
- Include a suitable viability dye.
- Titrate every antibody.
- Match fluorophore brightness to marker expression.
- Evaluate sample autofluorescence.
- Include appropriate unstained and single-stained controls.
- Use FMOs for gates that are difficult to define.
- Include biological positive and negative controls.
- Exclude debris, doublets, and dead cells.
- Acquire enough events for the populations being studied.
- Review compensation or spectral unmixing before biological interpretation.
- Measure treatment effects within clearly identified populations.
- Keep tissue processing consistent across comparison groups.
- Record instrument settings and quality-control results.
- Validate the complete panel rather than only individual antibodies.
- Confirm important results using functional or complementary methods.
- Use validated clinical workflows when results are intended for patient care.
- Document the complete gating and analysis strategy.
Improving Cancer Research Through Flow Cytometry
Flow cytometry provides a flexible method for studying cancer cells, immune cells, and the interactions between them.
It can be used to investigate blood cancers, solid tumors, the tumor immune microenvironment, drug responses, apoptosis, proliferation, signaling, therapeutic targets, residual disease, and cell-therapy products.
Its greatest advantage is the ability to measure several characteristics on individual cells within a complex sample.
This can reveal rare populations and biological differences that may be hidden by measurements that average all cells together.
However, reliable cancer flow cytometry requires careful sample preparation, validated antibodies, appropriate controls, sufficient event collection, thoughtful gating, and accurate interpretation.
When these factors are carefully controlled, flow cytometry can provide detailed information about cancer-cell identity, immune responses, treatment effects, and cellular heterogeneity throughout the research process.